EMA starts new benefit-risk assessment of flupirtine

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2017年 / 1677卷 / 1期
关键词：
D O I：
10.1007/s40278-017-38280-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [41] Benefit-risk assessment of antileukotrienes in the management of asthma
    García-Marcos, L
    Schuster, A
    Pérez-Yarza, EG
    DRUG SAFETY, 2003, 26 (07) : 483 - 518
  • [42] A benefit-risk assessment of basiliximab in renal transplantation
    Boggi, U
    Danesi, R
    Vistoli, F
    Del Chiaro, M
    Signori, S
    Marchetti, P
    Del Tacca, M
    Mosca, F
    DRUG SAFETY, 2004, 27 (02) : 91 - 106
  • [43] Benefit-risk assessment of zaleplon in the treatment of insomnia
    Barbera, J
    Shaprio, C
    DRUG SAFETY, 2005, 28 (04) : 301 - 318
  • [44] Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia
    Joseph Barbera
    Colin Shapiro
    Drug Safety, 2005, 28 : 301 - 318
  • [45] Benefit-Risk Assessment of Antileukotrienes in the Management of Asthma
    Luis García-Marcos
    Antje Schuster
    Eduardo G. Pérez-Yarza
    Drug Safety, 2003, 26 : 483 - 518
  • [46] Benefit-Risk Assessment of Diacerein in the Treatment of Osteoarthritis
    Panova, Elena
    Jones, Graeme
    DRUG SAFETY, 2015, 38 (03) : 245 - 252
  • [47] Interactive dashboards for vaccine benefit-risk assessment
    Reactions Weekly, 2018, 1696 (1) : 8 - 8
  • [48] The EMA's CHMP concludes that the benefit-risk balance for MabThera [rituximab] remains positive,
    Reactions Weekly, 2012, 1404 (1) : 3 - 3
  • [49] The EMA confirms that Revlimid's [lenalidomide's] benefit-risk balance remains positive,
    Reactions Weekly, 2011, 1371 (1) : 3 - 3
  • [50] A new framework to address challenges in quantitative benefit-risk assessment for medical products
    Fu, Bo
    Li, Xuefeng
    Scott, John
    He, Weili
    CONTEMPORARY CLINICAL TRIALS, 2020, 95
12345